Our Fisher Clinical ServicesSM offerings are now part of the Patheon brand portfolio by Thermo Fisher Scientific. Please update your bookmark.
Small Pharma, Big Opportunity: Should CDMO Partner Size Influence Selection for your Large Molecule Project?
Overview: With resource constraints and process development challenges within early development, new & emerging companies are often left with the difficult decision on whether to select a small or large CDMO for their steriles drug product. This critical decision not only has implications within early development , but also with scale-up and commercialization.